06:00 PM EDT, 04/01/2025 (MT Newswires) -- Inhibrx Biosciences ( INBX ) said late Tuesday that Brendan Eckelman, its co-founder and chief scientific officer, will leave the company to form a private biotechnology firm that signed an exclusive license agreement with Inhibrx.

The deal is for the rights to certain technologies no longer being pursued by Inhibrx. The pact includes an upfront payment upon completion of the initial funding of Eckelman's new company and other future development milestones.

Carlos Bais, Inhibrx's executive vice president of translational sciences, will be appointed chief scientific officer and David Matly will become president, in addition to his existing role as chief commercial and business development officer.